Healthy adults
Conditions
Interventions
Drink fermented milk containing only Lactobacillus salivarius L55 once daily after a meal.
Drink placebo once daily after a meal.
Sponsors
IMEQRD Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 20 to 64 years old (at the time of submission of an informed consent document). 2. Japanese males and females. 3. Those who have symptoms, such as itchy eyes and a blocked or runny nose, in their everyday lives, but those who are healthy and have no chronic somatic disorders. 4. Body mass index (BMI) of less than 30 kg/m2 5. Non-smokers (which include electronic cigarette users) 6. Those who can collaborate on 12-week ingestion of test food. 7. Those who have a device available for an electronic diary and who can input their own data into the device. 8. Those who receive a full explanation of the purpose and content of this clinical trial, those who desire and voluntarily request to participate in this clinical trial with a full understanding of its explanation, those who have the capability to consent, and those who can give their written informed consent. 9. Those who were judged as non-diseased individuals by the principal investigator or a sub-investigator and those who were determined to be suitable for participation in this clinical trial.
Exclusion criteria
Exclusion criteria: 1. Those who were categized into "severe" or "the most severe" according to the classification of allergic rhinitis based on severity of symptoms. 2. Those who have acute rhinitis, sinusitis, nasal polyp, hypertrophic rhinitis, and deviated septum. 3. Those who have bronchial asthma as a complication. 4. Those who have the serious disorders of the liver, heart, kidney, respiratory system, endocrine, and metabolism. 5. Those who currently receive or have previously received allergen immunotherapy. 6. Those who currently take some kind of medication for therapeutic purposes. 7. Those with a past and current medical history of drug or food allergy. 8. Those who ingest Lactobacillus preparations, Lactobacillus supplements, yogurts, foods for specified health use, and foods with function claims on a daily basis (however, at the time of submission of an informed consent document, those who can stop ingesting foods listed above during the study period are excluded). 9. Those who are currently pregnant or breastfeeding or those who desire a pregnancy during the study period. 10. Those who have experienced a feeling sick or health deterioration due to blood sampling. 11. Those who have diarrhea by dairy products and those who have lactose intolerance. 12. Those who participated in another clinical trial within one month before our screening test and those who took an active ingredient provided in the clinical trial. 13. Those who may undergo lifestyle changes (such as a long trip) during the study period. 14. Those who were determined by the principal investigator to be unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eye and nasal symptom questionnaire ,The Japanese Rhinoconjunctivitis Quality of Life Questionnaire version 2002 (JRQLQ No1) | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of the nasal cavity (mucosal swelling and mucosal color of the inferior turbinate, serous fluid volume, and characteristics of nasal discharge) | — |
Countries
Japan
Contacts
Public ContactYoshitada Hira
IMEQRD Co., Ltd Planning and Sales Department
Outcome results
None listed